The causes of ischemic stroke are widely diverse, ranging from large artery atherosclerosis to cardioembolism, and it is important to use preventive therapy toward the goal reducing the future risk of recurrent ischemic stroke, myocardial infarction, and vascular death. Antithrombotic therapy is one of the fundamental medical approaches for secondary prevention of ischemic stroke, which is broadly divided into two general categories, those that exert their effect via platelet inhibition (antiplatelet agents), and those that influence various factors in the clotting cascade (anticoagulants). In general, the clinical guidelines recommend antiplatelet agents for patients with non-cardioembolic stroke, while anticoagulants is indicated for patients with presumed or proven cardioembolic stroke. 
Antiplatelet agent For patients with non-cardioembolic ischemic stroke or TIA, aspirin (50∼300 mg) can be given to prevent stroke recurrence and further vascular events. For patients with non-cardioembolic ischemic stroke, aspirin or clopidogrel monotherapy can be given as initial therapy. For patients allergic to aspirin, clopidogrel is reasonable as alternative antiplatelet agent. Ticlopidine is more effective than aspirin in the prevention of stroke recurrence. However, caution should be used with the occurrence of side effect such as neutropenia. Cilostazol monotherapy can be used for patients with non-cardioembolic ischemic stroke, especially lacunar stroke. For patients unable to be treated by aspirin and clopidogrel, cilostazol or triflusal may be used as alternative antiplatelet agent. For patients who have higher bleeding risk, cilostazol or triflusal is recommended to prevent stroke recurrence. 여되는 경우에는 항응고제 사용의 적응증에서 제외된다 (Fig. 2) . 
